PTC Therapeutics, Inc. (PTCT)
| Market Cap | 5.64B |
| Revenue (ttm) | 1.73B |
| Net Income (ttm) | 682.64M |
| Shares Out | 82.77M |
| EPS (ttm) | 7.78 |
| PE Ratio | 8.77 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 852,141 |
| Open | 67.65 |
| Previous Close | 68.10 |
| Day's Range | 67.28 - 69.43 |
| 52-Week Range | 35.95 - 87.50 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 79.41 (+16.45%) |
| Earnings Date | Feb 19, 2026 |
About PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price target is $79.41, which is an increase of 16.45% from the latest price.
News
PTC Therapeutics to Participate at Upcoming Investor Conferences
WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care Conferen...
PTC Therapeutics: Sephience As A Major Growth Driver
PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for Hun...
PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript
PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
– Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respec...
PTC Therapeutics Provides Regulatory Update on Translarna™
WARREN, N.J., Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the t...
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026
WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 fi...
PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M – – Unaudited 2025 total product and royalty revenue of approximately $823M, exceeding guidance – – 2026 p...
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Jan. 8, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each representing the r...
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan
– Indication includes all ages and the full spectrum of disease severity – – First Japan product approval for PTC – WARREN, N.J. , Dec. 22, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) a...
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
WARREN, N.J. , Dec. 18, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B.
PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript
PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoag...
Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600
NEW YORK , Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: S&P SmallCap 600 constituent Sandisk Corp. (NASD: SNDK) will replace T...
PTC Therapeutics to Host R&D Day
Event to take place on Dec. 2, 2025 in New York City WARREN, N.J. , Nov. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host an R&D Day to discuss its pipe...
PTC Therapeutics, Inc. (PTCT) Presents at UBS Global Healthcare Conference 2025 Transcript
PTC Therapeutics, Inc. ( PTCT) UBS Global Healthcare Conference 2025 November 11, 2025 3:30 PM EST Company Participants Matthew Klein - CEO & Director Conference Call Participants Ashwani Verma - UBS...
PTC Therapeutics, Inc. (PTCT) Q3 2025 Earnings Call Transcript
PTC Therapeutics, Inc. ( PTCT) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Ellen Cavaleri Matthew Klein - CEO & Director Eric Pauwels - Chief Business Officer Pierre Gravi...
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
– Initiated US and EU launch of Sephience™ (sepiapterin) – – Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30 – – Robust Q3 performance w...
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results
WARREN, N.J. , Oct. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2025 financial resul...
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
On Saturday, BioMarin Pharmaceutical Inc. BMRN released new Phase 3 PEGASUS study results on Saturday.
PTC Therapeutics, Inc. (PTCT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
PTC Therapeutics, Inc. (NASDAQ:PTCT) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief F...
PTC Therapeutics, Inc. (PTCT) Presents At Cantor Global Healthcare Conference 2025 Transcript
PTC Therapeutics, Inc. (NASDAQ:PTCT) Cantor Global Healthcare Conference 2025 September 3, 2025 8:35 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Office...
PTC Therapeutics, Inc. (PTCT) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
PTC Therapeutics, Inc. (NASDAQ:PTCT) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 11:00 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Finan...
PTC Therapeutics Stock Is Stuck In A Multi-Year Slump
PTC Therapeutics PTCT is currently in the final 18th phase of its Adhishthana cycle on the weekly chart, and the outlook remains bleak. Signals point to prolonged underperformance, with weakness likel...